|2.02||-0.0801||-3.81%||Vol 47.49K||1Y Perf 588.56%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||2.00||Analyst Rating||Strong Buy 1.00|
|Potential %||-0.99||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/100||Value Ranking||★ 37.68|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/100||Income Ranking||— -|
|Price Range Ratio 52W %||2.58||Earnings Rating||Buy|
|Market Cap||3.89M||Earnings Date||6th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th Nov 2023|
|Estimated EPS Next Report||-1.58|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||66.72K|
|Avg. Monthly Volume||47.62K|
|Avg. Quarterly Volume||49.20K|
Agile Therapeutics Inc. (NASDAQ: AGRX) stock closed at 2.1001 per share at the end of the most recent trading day (a -18.92% change compared to the prior day closing price) with a volume of 46.09K shares and market capitalization of 3.89M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 15 people. Agile Therapeutics Inc. CEO is Alfred Altomari.
The one-year performance of Agile Therapeutics Inc. stock is 588.56%, while year-to-date (YTD) performance is 825.15%. AGRX stock has a five-year performance of 438.49%. Its 52-week range is between 1.65 and 16, which gives AGRX stock a 52-week price range ratio of 2.58%
Agile Therapeutics Inc. currently has a PE ratio of 0.00, a price-to-book (PB) ratio of 1.81, a price-to-sale (PS) ratio of 1.76, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -270.54%, a ROC of -356.40% and a ROE of -875.51%. The company’s profit margin is -%, its EBITDA margin is -785.10%, and its revenue ttm is $6.89 Million , which makes it $0.17 revenue per share.
Of the last four earnings reports from Agile Therapeutics Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-1.58 for the next earnings report. Agile Therapeutics Inc.’s next earnings report date is 06th Nov 2023.
The consensus rating of Wall Street analysts for Agile Therapeutics Inc. is Strong Buy (1), with a target price of $2, which is -0.99% compared to the current price. The earnings rating for Agile Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Agile Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Agile Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 21.15, ATR14 : 0.23, CCI20 : 64.17, Chaikin Money Flow : 0.04, MACD : -0.02, Money Flow Index : 63.10, ROC : 0.48, RSI : 48.07, STOCH (14,3) : 47.88, STOCH RSI : 0.44, UO : 54.28, Williams %R : -52.12), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Agile Therapeutics Inc. in the last 12-months were:
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.